Carlayne E Jackson
Overview
Explore the profile of Carlayne E Jackson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
1263
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shefner J, Oskarsson B, Macklin E, Chibnik L, Quintana M, Saville B, et al.
JAMA
. 2025 Mar;
PMID: 40067755
Importance: Amyotrophic lateral sclerosis (ALS) is a fatal disease. The sigma-1 (σ1) receptor emerged as a target for intervention. Objective: To determine the effects of pridopidine, a σ1-receptor agonist, in...
2.
Verdiperstat in Amyotrophic Lateral Sclerosis: Results From the Randomized HEALEY ALS Platform Trial
Andrews J, Paganoni S, Macklin E, Chibnik L, Quintana M, Saville B, et al.
JAMA Neurol
. 2025 Mar;
PMID: 40067754
Importance: Myeloperoxidase is one of the most abundant peroxidase enzymes in activated myeloid cells. Myeloperoxidase inhibitors may have a clinical benefit in amyotrophic lateral sclerosis (ALS) by slowing neurodegeneration via...
3.
Paganoni S, Fournier C, Macklin E, Chibnik L, Quintana M, Saville B, et al.
JAMA Netw Open
. 2025 Feb;
8(2):e2459058.
PMID: 39960672
Importance: The etiology of amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease, is unknown. However, neuroinflammation and complement activation may play a role in disease progression. Objective: To determine the...
4.
Busis N, Bickel J, Jackson C
Lancet Neurol
. 2025 Jan;
24(2):99.
PMID: 39862894
No abstract available.
5.
Hromas G, Jackson C, Cooper D, Sullivan A
Appl Neuropsychol Adult
. 2024 Jan;
:1-4.
PMID: 38241787
Objective: Approximately 50% of patients with amyotrophic lateral sclerosis (ALS) experience cognitive decline, with frontotemporal dementia (FTD) accounting for up to 15% of these cases. Despite this, there is considerable...
6.
Pattee G, Genge A, Couratier P, Lunetta C, Sobue G, Aoki M, et al.
Expert Rev Neurother
. 2023 Aug;
23(10):859-866.
PMID: 37646130
Introduction: Amyotrophic lateral sclerosis (ALS) is a progressive and incurable neurodegenerative disease. While pharmacotherapy options remain limited, the Food and Drug Administration (FDA) approved intravenous (IV) and oral edaravone for...
7.
Shefner J, Al-Chalabi A, Andrews J, Chio A, de Carvalho M, Cockroft B, et al.
Amyotroph Lateral Scler Frontotemporal Degener
. 2023 May;
24(5-6):523-534.
PMID: 37254449
: To determine the target population and optimize the study design of the phase 3 clinical trial evaluating in participants with amyotrophic lateral sclerosis (ALS).: We evaluated the phase 2...
8.
Gebrehiwet P, Meng L, Rudnicki S, Sarocco P, Wei J, Wolff A, et al.
J Med Econ
. 2023 Mar;
26(1):488-493.
PMID: 36930042
Aims: To estimate the health utilities and quality-adjusted life years (QALYs) in patients with amyotrophic lateral sclerosis (ALS) receiving versus placebo in FORTITUDE-ALS. Materials And Methods: We performed a post...
9.
Genge A, Pattee G, Sobue G, Aoki M, Yoshino H, Couratier P, et al.
Muscle Nerve
. 2022 Dec;
67(2):124-129.
PMID: 36504406
Introduction/aims: An intravenous (IV) formulation of edaravone has been shown to slow the rate of physical functional decline in amyotrophic lateral sclerosis (ALS). An oral suspension formulation of edaravone was...
10.
Gebrehiwet P, Meng L, Rudnicki S, Sarocco P, Wei J, Wolff A, et al.
Amyotroph Lateral Scler Frontotemporal Degener
. 2022 Dec;
24(3-4):304-310.
PMID: 36503310
Objective: To evaluate the Milano-Torino staging (MiToS) and King's staging systems as potential outcome measures for clinical trials in amyotrophic lateral sclerosis (ALS) by assessing these outcomes in FORTITUDE-ALS. Methods:...